Thermo Fisher (TMO): Paying 35 Times for the Lab Standard

Thermo Fisher trades around $651.45 as I write this, 1.8% below its 52-week high of $664 and roughly 50% above its 52-week low of $435. A stock that close to its high is not being priced like a company anyone doubts.

A piece of equipment stamped Thermo Fisher sits in almost every biotech lab, hospital testing floor and drug manufacturing plant I have looked at. That ubiquity, more than any single product line, is the whole reason the stock rarely trades cheap.

My thesis: Thermo Fisher’s growth picked up this year, but at 35.1 times earnings the stock has already priced that speed in, so buying here is a bet the pace holds, not a bet the market wakes up to something it missed.

What Thermo Fisher actually sells now

The company’s latest annual report on SEC EDGAR splits the business into four pieces for fiscal 2025. Laboratory Products and Biopharma Services, the equipment and services labs reorder constantly, made up 52% of revenue. Life Sciences Solutions, the reagents and consumables that go into every experiment, was 22%. Analytical Instruments, the big-ticket machines a lab budgets for once, contributed 16%. Specialty Diagnostics was the smallest piece at 10%.

That mix matters more than it looks. More than half of sales come from products a lab reorders instead of a single instrument it approves once and forgets about. Revenue does not swing hard when one customer delays a capital purchase, because most of the business behaves like a subscription even though nobody prices it that way.

That is the moat. It is boring, and it works.

I read the switching costs as the real reason it holds up. A hospital lab or a biopharma manufacturer that has validated a piece of equipment against a regulatory filing does not swap suppliers to save a percentage point on a reagent order, because requalifying that process with the FDA or a customer’s own quality team costs more than the savings would return. That inertia is worth more to Thermo Fisher than any single product win.

The brand recognition behind that inertia took decades to build. A competitor with a cheaper price list still has to convince a compliance department to redo work nobody wants to redo, and that is a much harder sale than it sounds.

Growth accelerated in the June quarter

Zoom out and the multi-year shape is more interesting than one good quarter. Revenue was $44.9 billion in 2022, fell to $42.9 billion in 2023 as pandemic-era testing demand faded, stayed flat at $42.9 billion in 2024, and only turned higher this year at $44.6 billion. Thermo Fisher spent three years working off a COVID hangover before this acceleration showed up. That context matters: 11% quarterly growth reads less like a new secular trend to me and more like a business finally climbing back to where it already was, plus a bit more on top.

Full-year 2025 revenue was $44.6 billion, up 4% from $42.9 billion in 2024. That is a modest number for a company this size, and by itself it does not explain a stock sitting near its high.

The June quarter is why. Revenue was $12.0 billion, up 11% from the same quarter a year earlier and 9% higher than the prior quarter. Analysts model $21.71 in earnings per share over the next year against $18.58 trailing, which implies 17% growth if the estimate holds.

The stock reacted the way you would expect. Shares moved +8.7% on the July 23 report, sizably above the company’s own average earnings-day move of 5.5%. A market does not usually swing that far past its own history on a report unless something in the numbers surprised it.

I made almost the same argument about a company growing far faster in Palantir’s growth is real, and so is the valuation problem: a business can be doing everything right and the stock can still be priced for more than right.

What 35 times earnings is buying

Trailing earnings put the stock at 35.1 times, above its own five-year average of 31.5. On next year’s estimate the multiple falls to 30.0, which is the more useful number if you believe the growth holds, and the market is pricing this stock as though it does.

Price to sales sits at 4.9, almost exactly its own five-year average. That is the one multiple that has not moved, and it tells me something specific: investors are not assigning Thermo Fisher a richer sales multiple, they are simply willing to pay more per dollar of profit because they expect more of those dollars to show up.

Not every expensive stock earns the label the same way. Tesla’s premium rests on a story about a future product mix; Thermo Fisher’s rests on a growth rate that already happened last quarter. I would rather pay up for the second kind. Paying up is still paying up.

This is not an income stock dressed up as a growth story either. A 0.28% dividend yield returns a fraction of what a money-market fund pays today, so anyone buying Thermo Fisher is buying the earnings growth and nothing else. Plenty of quality compounders pay next to nothing and still work out fine, but it does mean the whole return depends on the multiple holding or the earnings outrunning it, with no yield to cushion things if either one slips.

Wall Street’s target trails the stock

Eighteen analysts cover Thermo Fisher. 83% rate it a buy, which sounds bullish until you look at where they actually think the stock is going: an average target of $640, about -2% below where it trades now.

The spread tells the real story. The high estimate is $748, 15% above the current price. The low estimate is $520, -20% below it. That is roughly a 35-percentage-point gap between the most and least optimistic analyst covering the same stock, which means the group agrees the business is fine and disagrees sharply on what the multiple should be.

I have seen the opposite setup too, a stock priced well below its own target with a similar coverage split. JPMorgan at 15 times earnings traded 4.6% off its high with a target meaningfully above the price; Thermo Fisher is close to the mirror image, sitting near the target ceiling most of its own followers have already reached.

Short interest sits at just 1.5% of the float. That tells me skeptics are not making an active bet against this stock right now, so the risk here, if there is one, looks more like complacency than a crowded short squeeze waiting to unwind.

At a $240.9 billion market cap, this is a mega-cap name that shows up in nearly every healthcare-sector fund, active or passive. That ownership base usually means steadier trading and less panic on a single data point, but it also means a broad de-rating of expensive healthcare-adjacent stocks would drag this one down even if nothing at Thermo Fisher itself changed.

The margin number that would break my case

Here is where I would be wrong. Gross margin was 40.9% in the most recent period, down from 41.3% a year earlier. Operating margin held at 18% and net margin at 15%, so nothing has broken yet.

But a rising-revenue, falling-margin combination is exactly what shows up before a company starts discounting for volume instead of selling on demand. I do not know yet whether that slip is mix, with lower-margin diagnostics or instruments growing faster than higher-margin consumables, or actual price pressure from biotech and hospital customers watching their own budgets. The data available to me does not separate the two causes, and that is the honest gap in this thesis.

If gross margin drops another leg next quarter while revenue growth stays in double digits, I would read that as the company buying its growth back with price rather than winning it with demand, and I would stop trusting the acceleration story until margin stabilizes.

Specialty Diagnostics, the smallest segment at 10% of sales, tends to carry a different margin profile than the instrument-heavy segments, and the reporting I have does not break out segment-level margin cleanly enough for me to isolate that effect from pure pricing. That is an admission, not an excuse. When a filing does not give me the number I actually need, the honest move is to say so rather than guess and present the guess as fact.

Metric	Value	Context
Price	$651.45	1.8% below 52-week high of $664
P/E (trailing)	35.1	five-year average 31.5; forward 30.0
Price/sales	4.9	five-year average 4.9
Quarterly revenue	$12.0 billion	up 11% year over year
Gross margin	40.9%	prior year 41.3%
Analyst target (avg)	$640	-2% vs current price, 18 analysts
Dividend yield	0.28%	not the reason to own this stock

None of this makes Thermo Fisher a sell. The business is durable, the growth is real, and a 0.28% dividend yield was never the reason to own it anyway. What would change my mind is the next quarterly report: watch gross margin against that 40.9% line and revenue growth against 11%. Hold both and the multiple probably holds too. Lose either one and a stock sitting 1.8% off its high has more room to fall than to rise.

Analysis and opinion only, not investment advice. Figures in this piece come from Thermo Fisher’s filings on SEC EDGAR and its investor site; valuation multiples are approximate and were checked on September 18, 2026.